Concise approach for the synthesis of Voxelotor for sickle cell disease

被引:1
|
作者
Manda, Jagadish [1 ,2 ]
Reddy, Basi V. Subba [1 ]
机构
[1] CSIR Indian Inst Chem Technol, Fluoroagrochem Dept, Hyderabad 500007, India
[2] Acad Sci & Innovat Res AcSIR, Ghaziabad 201002, India
关键词
Sickle cell disease; Pyridine-2; 3-carboxylic anhydride; 3-Methylpicolinic acid; 2-(1 H -pyrazol-3-yl)pyridine; Voxelotor;
D O I
10.1016/j.tet.2023.133768
中图分类号
O62 [有机化学];
学科分类号
070303 ; 081704 ;
摘要
A novel approach has been developed for the synthesis of Voxelotor, which is used for the treatment of Sickle Cell Disease (SCD). The key steps involved in this approach are the ring opening of 2,3-pyridinedicarboxylic anhydride with isopropanol, the formation of pyrazole ring from N,N-dimethylenamino ketone and hydrazine.hydrate, the regioselective N-isopropylation of pyrazole ring and the O-alkylation of 2,6-dihydroxybenzaldehyde. Alternatively, a protecting group free approach for the synthesis of key intermediates 8 and 14 of Voxelotor has been developed.
引用
收藏
页数:6
相关论文
共 50 条
  • [21] Expanded eligibility for emerging therapies in sickle cell disease in the UK - crizanlizumab and voxelotor
    Vora, Sona M.
    Boyd, Stephen
    Denny, Nicholas
    Jackson, Elizabeth
    Roy, Noemi B. A.
    Howard, Jo
    Lugthart, Sanne
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 (04) : 502 - 504
  • [22] GBT1118, a Voxelotor Analog, Ameliorates Hepatopathy in Sickle Cell Disease
    Haroun, Elio
    Lim, Seah H.
    Dutta, Dibyendu
    MEDICINA-LITHUANIA, 2024, 60 (10):
  • [23] Voxelotor use in adults with sickle cell disease in a real-world setting
    Curtis, Susanna A.
    Betancourt, Jaime
    Kottapalli, Niharika
    Campbell, Sean
    Minniti, Caterina
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (03) : E125 - E128
  • [24] Real-world data on voxelotor to treat patients with sickle cell disease
    Muschick, Kathryn
    Fuqua, Tranaka
    Stoker-Postier, Carrianne
    Anderson, Alan R.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2022, 109 (02) : 154 - 161
  • [25] Acute venous thromboembolism after initiation of voxelotor for treatment of sickle cell disease
    Lemon, Natalie
    Sterk, Ethan
    Rech, Megan A.
    AMERICAN JOURNAL OF EMERGENCY MEDICINE, 2022, 55 : 225.e1 - 225.e3
  • [26] Real-World Experience of Voxelotor for the Management of Complications in Sickle Cell Disease
    Shah, Nirmish
    Lipato, Thokozeni
    Alvarez, Ofelia A.
    Delea, Thomas
    Lonshteyn, Alexander
    Weycker, Derek
    Nguyen, Andy
    Beaubrun, Anne
    Agodoa, Irene
    BLOOD, 2021, 138
  • [27] Real-World Effectiveness of Voxelotor for Treating Sickle Cell Disease in the US
    Zaidi, Ahmar Urooj
    Lipato, Thokozeni
    Alvarez, Ofelia A.
    Lonshteyn, Alexander
    Weycker, Derek
    Pham, Nhat
    Delea, Thomas E.
    Agodoa, Irene
    Cong, Ze
    Shah, Nirmish
    BLOOD, 2020, 136
  • [28] THE PHARMACOKINETICS OF VOXELOTOR FOLLOWING SINGLE DOSES IN PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE
    Washington, Carla
    Savic, Rada
    Green, Michelle
    Inati, Adlette
    Estepp, Jeremie
    Brown, Clark
    Hoppe, Carolyn
    Wang, Winfred
    Woods, Gerald
    Balaratnam, Ganesh
    Dixon, Sandra
    Fong, Erica
    Hutchaleelaha, Athiwat
    Tonda, Margaret
    Lehrer, Josh
    PEDIATRIC BLOOD & CANCER, 2018, 65
  • [29] Voxelotor as a new disease-modifying Therapy of Sickle Cell Anemia Comment
    Mytilineos, Joannis
    TRANSFUSIONSMEDIZIN, 2019, 9 (03) : 145 - +
  • [30] Urgent use of voxelotor in sickle cell disease when immediate transfusion is not safe
    Ferlis, Mica
    Lipato, Thokozeni
    Roseff, Susan D.
    Smith, Wally R.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2022, 109 (05) : 586 - 589